The COVID-19 pandemic has not only affected outpatient services, but also led to deferment of elective surgeries, and resulted in the loss of medical tourism, all of which would hit the FY21 financials.

In November, DRL registered growth of 28 per cent year-on-year (YoY), which was the highest among peers and double that of the industry growth (14.5 per cent).

Analysts feel Fortis Healthcare share holders are at a disadvantage and deal valuations had been short of expectations

L&T is the preferred pick, but given the opportunities in the power T&D space analysts are also positive on KEC, ABB and Kalpataru

Experts tell Ujjval Jauhari that investors need to be careful in picking stocks given high valuations and with markets possibly ignoring potential risks

Market cap touches Rs 5 lakh crore; earnings growth to spurt in FY19

The past eight months have seen vast improvement in the Indian economy, says Edelweiss Group chairman and chief executive Rashesh Shah, who feels domestic-oriented sectors are likely to do better.

Experts feel oil prices will remain volatile with an upward bias.

India has always been a good bet in relative terms during crises/turbulent times in emerging markets (EMs).

Cipla, though late in changing its strategy for international markets, has in recent years taken an inorganic route for expansion.

The fall in crude prices has added to the gains.

Gross refining margins may decline sequentially but improving petro-chem margins will boost earnings

Select companies in infra, capital goods, private banks, auto, oil & gas, and mining could be considered by investors.

Low gas prices and weakness in petchem margins lead to lower earnings estimates for GAIL.

Auction of blocks will also result in better price.

The sharp fall in oil price is positive for oil marketers as subsidy concerns reduce further.

Buy these stocks on any correction as both the companies have strong long-term prospects

The news that exports to the US will not restart before next year as well as the September quarter performance are sentiment dampeners.

Respiratory product paves way for launch in larger markets and greater earnings visibility.

While lower gas output led to earnings cuts, price rises with regular ramp-ups in output will lead to earnings upgrades